Silexion Therapeutics Corp(SLXN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:47 PM ET (Korea 10/31 08:47)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -56.54 | Insider Own | 40.68% | Shs Outstand | 15.2M | Perf Week | -23.11% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 58.2% | Insider Trans | - | Shs Float | 9.0M | Perf Month | -47.96% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -9.1 | Inst Own | 0.13% | Short Float | 1.8% | Perf Quarter | -92.55% |
| Income | -0.01B | P/S | - | EPS this Y | 45.93% | Inst Trans | 0.1% | Short Ratio | 0.02 | Perf Half Y | -97.57% |
| Sales | 0.00B | P/B | 3.89 | EPS next 5Y | 41.98% | ROA | -277.96% | Short Interest | 0.16M | Perf YTD | -99.24% |
| Book/sh | 0.04 | P/C | 0.98 | EPS past 3/5Y | - -38.17% | ROE | -17021.95% | 52W High | -99.58% ($34.60) | Perf Year | -99.56% |
| Cash/sh | 0.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | -5169.63% | 52W Low | 2.54% ($0.14) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 98.1% | Gross Margin | - | Volatility(W/M) | 15.75% 14.71% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.94 | EPS Q/Q | 88.04% | Profit Margin | - | RSI (14) | 32.14 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.94 | Sales Q/Q | - | SMA20 | -21.64% ($0.19) | Beta | -0.37 | Target Price | $50 |
| Payout | - | Debt/Eq | 35.25 | Earnings | 2026/8/14 | SMA50 | -48.92% ($0.29) | Rel Volume | 0.07 | Prev Close | $0.14 |
| Employees | 14 | LT Debt/Eq | 5.75 | EPS/Sales Surpr. | 75.61% - | SMA200 | -97.83% ($6.91) | Avg Volume(3M) | 10.09M | Price | $0.15 |
| IPO | 2021/4/7 | Option/Short | No/Yes | Trades | 641 | Volume | 741,914 | Change | 2.04% |
🧬 (Silenseed Therapeutics) is a US Nasdaq-listed clinical-stage biotech company developing targeted RNA silencing therapies for pancreatic cancer. Its lead candidate, SIL-204, is a next-generation siRNA-based therapeutic designed to target and degrade the mRNA of KRAS G12D and G12V mutations commonly found in pancreatic cancer. The company also holds the first-generation LODER™ clinical asset.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 7% of its average volume.
SLXN has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.9% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.1%.
Tap to view numbers
It ranks #574 of 597 in the industry
Based on market cap of $2M.
HCWB#571 HCW Biologics Inc $2M PER - 
APVO#572 Aptevo Therapeutics Inc $2M PER - 
REVB#573 Revelation Biosciences Inc $2M PER - SLXN#574 Silexion Therapeutics Corp $2M PER - 
ELAB#575 PMGC Holdings Inc $2M PER - 
FAQ
What kind of company is SLXN?
SLXN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLXN?
The market cap of SLXN is approximately $2M, ranking 5,789 within its sector.
What is the 52-week high and low for SLXN?
SLXN has recorded a 52-week high of $34.60 and a low of $0.14.
